VXRT) announced that it had dosed the first topic in the Phase 1 study of VXA-CoV2-1, the company’s oral, room temperature stable COVID-19 vaccine candidate. “data-reactid =” 12 “> On Tuesday, vaccine specialist vaccinated Vaxart (VXRT) announced that it had dosed the first topic in the Phase 1 study of VXA-CoV2-1
After the vaccine impressed in preclinical models, it is a timely announcement from Vaxart. While the small biotechnology lags significantly behind other, mostly larger competitors in its Covid-19 vaccine program, as recent events have shown, bringing a viable solution to the market is far from hassle-free.
Earlier this week, Johnson & Johnson stopped its Covid-19 vaccine candidate Phase 3 study due to an unexplained illness of a participant. This event was quickly followed by Eli Lily, who stopped enrolling in her Covid-19 treatment program due to security concerns.
Mayank Mamtani, the bigger players’ battle highlights the alternative option that Vaxart presents to investors. “data-reactid =” 19 “> For FBR Riley analyst Mayank Mamtani, the major players’ battle highlights the alternative option Vaxart presents to investors.
“As COVID-19 cases continue to increase WW, and leading programs from J&J and AZN experience speed bumps with late-stage, albeit temporary, developments, it becomes increasingly important to have more targets on target in the C-19 vaccine landscape and recommend investors diversify positions, including with alternative modalities, e.g. VXRT’s oral candidate, which not only has the potential to be self-administered, but is also room temperature stable and quickly scalable, providing significant storage and distribution benefits, particularly relevant in non-Western economies with limited health resources, ”commented Mamtani.
The Vaxart share has experienced a roller coaster ride in 2020. Despite rising by 1637% from year to date, the share price has actually retreated by over 60% since July-year highs. Mamtani believes that in addition to the withdrawal, its “valuation disruption compared to more advanced C-19 vaccine mates is an additional compelling buying opportunity.”
click here) “data-reactid =” 22 “> For this purpose, Mamtani VXRT is evaluating a purchase along with a price target of $ 22. Investors can get a massive gain of 262% in pocket if his dissertation unfolds over the next year. (To see Mamtani’s history, click here)
See VXRT stock analysis at TipRanks) “data-reactid =” 23 “> Overall, only one other analyst currently has an overview of Vaxart’s progress and also recommends buying the stock, so Vaxart has a moderate buy consensus rating supported by an average price target of $ 19.50. suggests potential upward 220% next year (See VXRT stock analysis on TipRanks)
Best shares to buy, a recently launched tool that unites all of TipRanks’ equity insights. “data-reactid =” 32 “> To find great ideas for healthcare stocks that trade at attractive valuations, visit TipRanks ‘Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.